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Antineutrophil cytoplasm antibody (ANCA)–associated
vasculitis (AAV) commonly results in glomerulonephritis, in
which neutrophils and monocytes have important roles.
The heterodimer calprotectin (S100A8/S100A9, mrp8/14)
is a Toll-like receptor-4 ligand found in neutrophils and
monocytes and is elevated in inflammatory conditions. By
immunohistochemistry of renal biopsies, patients with focal
or crescentic glomerular lesions were found to have the
highest expression of calprotectin and those with sclerotic
the least. Serum levels of calprotectin as measured by ELISA
were elevated in patients with active AAV and the levels
decreased but did not normalize during remission,
suggesting subclinical inflammation. Calprotectin levels in
patients with limited systemic disease increased following
treatment withdrawal and were significantly elevated in
patients who relapsed compared with those who did not. As
assessed by flow cytometry, patients with AAV had higher
monocyte and neutrophil cell surface calprotectin expression
than healthy controls, but this was not associated with
augmented mRNA expression in CD14þ monocytes or
CD16þ neutrophils. Thus, serum calprotectin is a potential
disease biomarker in patients with AAV, and may have a role
in disease pathogenesis.
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Antineutrophil cytoplasm antibody (ANCA)–associated vas-
culitis is characterized by small-vessel inflammation and
immune reactivity against the neutrophil and monocyte
components proteinase 3 (PR3) and myeloperoxidase (MPO).
ANCA activate neutrophils and monocytes in vitro,1 and are
capable of inducing disease in certain animal models.2,3
ANCA titers do not closely follow disease activity, as
patients in clinical remission frequently have persistent
ANCA positivity, and serial measurements have been
demonstrated to be of limited use during disease remission
in guiding individualized patient treatment.4 A recently
demonstrated transcriptional profiling of purified CD8þ T
cells has identified a subset of genes associated with a poor
prognosis, and is therefore a potential biomarker in ANCA–
associated vasculitis (AAV).5 Glomerulonephritis, a common
feature of AAV, is pauci-immune and characterized by
infiltration of glomerular monocytes/macrophages and
T cells.6 Importantly, the extent of glomerular inflamma-
tion on renal biopsy predicts renal outcome.7 The more
inflamed the glomeruli, with predominance of crescents or
focal necrosis, the better the renal outcome compared with
mixed and sclerotic lesions, suggesting that these lesions
respond the most to therapy. However, there are currently no
noninvasive means of monitoring the activity of those
proinflammatory glomerular-infiltrating leukocytes.
Calprotectin (S100A8/S100A9, MRP8/14) is a heterodimer
complex of 2 intracellular calcium-binding proteins S100A8
(MRP 8) and S100A9 (MRP 14). These proteins are expressed
by neutrophils, monocytes, and early differentiated macro-
phages.8,9 Phagocytes have been demonstrated to release this
complex after their interaction with activated, inflamed
endothelium.10 Once secreted, the complex binds to activated
endothelial cells via heparan sulfate proteogylcans,11,12 and
induces proinflammatory effects, such as increased secretion
of IL8, upregulation of ICAM-1, and further recruitment of
leukocytes. In addition, the interaction results in impairment
of the endothelial monolayer integrity and induction of both
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caspase-dependent and caspase-independent cell death
mechanisms resulting in both apoptosis and necrosis.13,14
These characteristics make calprotectin a potentially
important mediator of tissue damage in AAV, in which
endothelial activation and vascular damage are prominent. A
previous study demonstrated the formation of MRP8/MRP14
(calprotectin) complexes on glomerular infiltrating macro-
phages, which correlated with the severity of different forms
of glomerulonephritis,15 whereas in renal vasculitis most
activated macrophages express this complex and produce
TNFa and IL 1.16 In addition, high serum calprotectin levels
have been described in patients with systemic lupus erythe-
matosus (SLE), rheumatoid arthritis, renal allograft rejection,
juvenile idiopathic arthritis, and Kawasaki disease,17–22
whereas increasing levels have been associated with relapse
in juvenile-onset arthritis23 and decreasing levels with
improvements in joint swelling in rheumatoid arthritis.24
In this study, we report on serum calprotectin levels,
calprotectin surface expression on circulating leukocytes and
in renal biopsies, and calprotectin (S100A8 and S100A9) gene
expression in purified leukocyte subsets in patients with
active AAV, AAV in remission, and healthy controls. We
demonstrate that calprotectin is expressed on the surface of
leukocytes and in the serum at higher basal levels in patients
than in healthy controls, whereas disease activity is associated
with increasing serum levels. Glomerular inflammation is
characterized by infiltration with calprotectin-positive leu-
kocytes, and the extent of glomerular inflammation is closely
related to the degree of calprotectin expression. Overall, we
find that calprotectin is a potential novel biomarker of
disease activity in AAV, and the altered basal levels in patients
suggest a potential role in disease etiology.
RESULTS
Renal biopsy immunohistochemistry
Immunohistochemistry (IHC) was performed on renal
biopsies of 32 acute AAV patients. The patients were classified
according to the Berden classification as follows: focal
(n¼ 4), crescentic (n¼ 12), mixed (n¼ 8), and sclerotic
(n¼ 4). In addition, there were four patients with no active
lesions.
Calprotectin positivity was localized to active glomerular
lesions, found within crescents or in areas of endocapillary
proliferation (Figure 1a (v and vi)). Sclerotic lesions were
generally negative for calprotectin expression (Figure 1a (iv)).
There was a statistically significant difference between the
levels of expression in the crescentic lesions compared with
the sclerotic or inactive lesions (Figure 1e) (Po0.01, one-way
analysis of variance (ANOVA)), whereas there was a trend
to lower levels of expression with decreasing degrees of
inflammation. Patients with globally sclerosed renal lesions
did not demonstrate significant calprotectin staining despite
the presence of CD68þ cells on the renal biopsy in 75%
(3 out of 4) of the patients (Figure 1a (i and iv)). There were
varying amounts of interstitial staining depending on the
extent of active tubulointerstital nephritis, whereas there was
particularly prominent calprotectin staining around active,
necrotizing small vessels (Figure 1b). The recent AAV histo-
logical classification has been shown to predict long-term
renal outcome, with best renal survival in focal lesions
followed by crescentic lesions, and our data indicate that
calprotectin expression effectively mirrors the histological
findings, with the greatest staining in the crescentic lesions
followed by focal lesions. Scarred glomeruli lack calprotectin
expression, but may still contain CD68-positive macrophages,
and are associated with poor long-term renal survival.
The calprotectin staining pattern was predominantly
glomerular, and in a similar glomerular distribution to that
of CD68-positive macrophages (Figure 1c (i and iii)).
Although some of the glomerular calprotectin-positive cells
also were positive for the neutrophil marker CD15 (ii), more
of the cells were positive for macrophage CD68 (i). Double
staining was performed, which demonstrated some CD15-
positive cells within the glomeruli (Figure 1d (i)), which were
positive for calprotectin, with greater numbers of glomerular
CD68-positive cells, many of which were calprotectin positive
(Figure 1d (ii and iii)). By contrast, many interstitial
macrophages were negative for calprotectin.
AAV patients demonstrate high calprotectin levels during
acute disease, which diminishes during remission but does
not normalize
Serum was obtained from AAV patients with acute disease
(n¼ 57) (32 patients from London, 25 patients from
Cambridge), disease remission (n¼ 57), and healthy controls.
Twenty-six patients had sequential samples (acute and
remission), with 17 patients having sequential samples
measured within the first year from diagnosis. Table 1 shows
the patient characteristics.
The median and ranges of calprotectin levels were as
follows: healthy controls, 2836 ng/ml (range 1058–6175);
acute AAV patients, 13,453 ng/ml (4769–40,000); and remission
AAV patients, 8957ng/ml (3860–25,083). There were significant
differences between healthy control and both acute and
remission AAV sera, as well as between acute and remission
samples (one-way ANOVA Po0.001) (Figure 2a). In addition,
there was a significant correlation between serum calprotectin
levels and total neutrophil count (r¼ 0.29; Po0.05). There
was no correlation with blood monocyte count or serum
creatinine. We also measured serum calprotectin in 59 patients
maintained on chronic hemodialysis who demonstrated
significantly lower levels of calprotectin than those patients
with both active and inactive AAV (both Po0.001).
Seventeen patients had serum calprotectin measured at
more than one time point within the first year after diagnosis
(Figure 2b). One patient had an increase in serum
calprotectin at week 19, which correlated with a clinical
relapse and requirement for escalated immunosuppression.
In the patients who entered remission, there was a decrease in
serum calprotectin levels from presentation to 4–6 months
during remission (Po0.05). The ANCA titer decreased in all
the patients (Figure 2c). There was no difference in
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Figure 1 | Immunohistochemistry to demonstrate the presence of calprotectin positive cells in the renal biopsy of patients with
antineutrophil cytoplasm antibody (ANCA)–associated vasculitis (AAV) glomerulonephritis. (a) Paired immunohistochemistry on renal
biopsy specimens for CD68 (i–iii) and calprotectin (MRP8/14) (iv–vi) from sclerotic (sequential) sections from the same biopsy seen in (i, iv)
crescentic, (ii, v) focal, and (iii, vi) glomerular lesions. Sclerosed glomeruli containing (i) CD68 macrophages but (iv) with an absence of
calprotectin-positive cells. Within and around a crescent, there is a (ii) heavy CD68 macrophage infiltrate, (v) with prominent expression of
calprotectin-positive cells in the crescentic lesion. Focal glomerulonephritis with the presence of (iii) CD68- and (vi) calprotectin-positive cells.
(b) Immunohistochemistry for calprotectin showing prominent staining around a small vessel. Black arrows point to some of the infiltrating
calprotectin-positive cells. (c) Immunohistochemistry for (i) monocyte/macrophages (CD68), (ii) neutrophils (CD15), and (iii) calprotectin (MRP8/
14)-staining cells in serial sections of one renal biopsy from a patient with acute crescentic ANCA-associated glomerulonephritis demonstrating
that most of the glomerular calprotectin staining appears to correlate with areas of CD68 staining. (d) Double staining of renal biopsies.
(i) CD15 staining (brown) and calprotectin (red) demonstrating some double-positive cells (black arrows), and a population of cells positive for
calprotectin but negative for CD15 (white arrows). (ii, iii) Biopsies of mixed and focal glomerulonephritis showing macrophage staining (brown)
and calprotectin (red). These sections demonstrate different macrophage populations, with some cells staining for both markers (black arrows)
and some interstitial macrophages not expressing calprotectin (white arrows in (ii)). (e) Graph demonstrates the glomerular calprotectin scoring
of renal biopsies according to the Berden biopsy classification of focal, crescentric, mixed, and sclerotic glomerular lesions. Biopsies not
demonstrating any current active AAV were also included.
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calprotectin levels in those acute patients in whom pred-
nisolone had already been initiated in the previous week
compared with those who were yet to commence immuno-
suppression.
There were no sufficient recorded relapses in this cohort to
investigate whether calprotectin may be a useful predictor of
disease relapse. We therefore used serum samples taken from
patients enrolled in the European Vasculitis Society (EUVAS)
Nonrenal Wegener’s Granulomatosis Treated Alternatively
with Methotrexate (NORAM) trial. This trial included
patients with limited systemic disease without renal involve-
ment who were treated for 12 months with immunotherapy
(either steroids and cyclophosphamide or steroids and
methotrexate), and in whom high relapse rates were recorded.
Patients had immunosuppression withdrawn at 12 months,
unless relapse had occurred. Follow-up was continued for a total
of 18 months.
Patients with relapsing-limited systemic disease demonstrate
higher calprotectin levels than those in remission
Samples were unavailable from the NORAM patients before
treatment initiation. However, samples from 27 patients were
available for analysis (out of 100 patients recruited), which
were taken at 1 month and 6 months of therapy when
treatment was with tapering doses of prednisolone from 60 to
25mg/day, as well as samples taken between 12 and
14 months, when immunosuppression had either been
withdrawn or was continued/restarted in those patients
who had already relapsed. Out of this group of 27 patients, 14
were relapsers and 13 were non-relapsers. The patients who
did not relapse had treatment stopped at 12 months. Five of
the relapsing patients relapsed before 12 months while on
immunosuppression, and 9 patients relapsed after 12 months
and restarted immunosuppression. Six of the late relapsers
had calprotectin measured before the relapse and before
reintroduction of immunosuppression.
In the NORAM patients’ samples, calprotectin levels
were significantly lower than in those with generalized
(renal) disease even during remission (median levels limited
disease at 1 month, 418 ng/ml (range 71–2167) compared
with generalized disease remission 8957 ng/ml (3860–25,083)
(Po0.0001). However, there was a significant increase
in calprotectin levels after 12 months (median level at
14 months, 1689 ng/ml (384–6245), vs. 1 month, 418 ng/ml
(range 71–2167)(Po0.0001, Mann–Whitney U test). The
14 patients who went on to relapse during the study (at a
median of 13 months from entry, range 6–18 months) had
significantly higher levels of calprotectin at the first two time
points, while on treatment, than the 13 non-relapsing
patients who were also on treatment at these time points
(both Po0.005) (Figure 2d). At the final time point, there
was a trend to higher values in the relapsers, but this did not
reach statistical significance (P¼ 0.055). These data indicate
that failure to sufficiently suppress calprotectin levels, while
on treatment, can predict subsequent relapse. Receiver
operating curves comparing relapsers with non-relapsers
demonstrated that at both 1 and 6 months there was a
threshold that was associated with a significant risk of
relapse: at 1 month a level4626 ng/ml was associated with a
sensitivity of 78.6% and specificity of 92.3% and a likelihood
ratio of 10.3, whereas at 6 months a level 4454 ng/ml was
associated with a sensitivity of 78.6% and specificity of
92.3%. Area under the curve at 1 month was 0.87, P¼ 0.0009,
whereas at 6 months it was 0.841, P¼ 0.002 (Figure 2). This
cohort of patients, unlike those with renal involvement,
consisted predominantly of PR3-ANCA-positive patients (25
PR3-ANCA positive, 1 MPO-ANCA, and 1 ANCA negative),
and the early samples were taken at a time when patients were
established on significant immunotherapy.
Neutrophil and monocyte surface expression of calprotectin
Surface expression was investigated in a subset of healthy
controls (n¼ 7), active AAV (n¼ 10), and remission AAV
(n¼ 18) patients. Twenty-three patients had renal disease,
whereas five had extrarenal disease with no renal involve-
ment. Fifteen were MPO-ANCA-positive and eight were
PR3-ANCA-positive, whereas five were ANCA negative.
Monocyte gates were determined on the flow cytometer by
counterstaining with CD14, lymphocyte gates were deter-
mined by a CD3 counterstain, and neutrophil gates were
identified by forward- and side-scatter characteristics
(Figure 3). There was a greater proportion (% of gated cells)
Table 1 | Characteristics of the patients with serum
calprotectin measurements
Acute, n¼ 57
Remission, n¼ 57
(70 samples)
Age 61 (16–84) 61 (16–85)
Gender
F 30 23
M 27 34
MPO-ANCA 21 33
PR3-ANCA 30 20
Both 2 0
ANCA negative 4 4
Median creatinine 185 124
Organ involvement
Renal and extrarenal 42 48
Extrarenal 15 9
Treatment at the time of sampling Nil 35 Nil 5
RTX, CYP, P 3 P and Aza 31
CYP, P 2 P and CYP 10
MMF 1 MMF 2
P/MP 10 Aza 4
P, MTX 3 P, RTX, CYP 1
P, AZA 1 P and MMF 5
P, CYP 2 P and MTX 3
P alone 2
RTX and P 4
RTX, P and Aza 2
RTX, P and MMF 1
Abbreviations: ANCA, active antineutrophil cytoplasm antibody; AZA, azathioprine;
CYP, cyclophosphamide; MMF, mycophenolate mofetil; MP, methylprednisolone;
MPO, myeloperoxidase; MTX, methotrexate; P, prednisolone; PR3, proteinase 3; RTX,
rituximab.
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of neutrophils and monocytes with detectable extracellular
expression of calprotectin in AAV patients during active
disease and convalescence compared with healthy controls
(percentage of neutrophils expressing calprotectin (median
(range)): healthy controls, 0% (0–3.6%); acute AAV, 78.9%
(14.7–98.1%); convalescence AAV, 6.8% (0–98.8%); active
AAV compared with controls, Po0.001; and active AAV
compared with convalescence AAV, Po0.05 (one-way
ANOVA) (Figure 3d); percentage of monocytes expressing
calprotectin (median (range)): healthy controls, 5.4%
(0–16.9%); acute AAV, 50.5% (0–91.6%); and convalescence
AAV, 5.6% (1–94.6%) (P¼NS) (Figure 3e). We were unable
to detect any surface calprotectin expression on CD3-positive
cells. Among patients, the decrease in the proportion of
monocytes expressing cell surface calprotectin between the
acute and convalescent samples was large but did not reach
statistical significance (Figure 3e). There was a statistically
significant difference in calprotectin mean fluorescent
intensity between acute patients and healthy controls for
both neutrophil (Po0.001) (Figure 3f) and monocyte
(Po0.01)(Figure 3g) cell surface expression. However, when
we compared the levels of S100A8 and S100A9 mRNA
extracted from purified patients’ CD16-positive neutrophils
and CD14-positive monocytes, from the Addenbrooke’s
hospital cohort, we found no correlation between serum
calprotectin and mRNA expression. Moreover, there were no
significant differences in mRNA expression between AAV
patients and healthy controls (data not shown).
DISCUSSION
Glomerular monocyte/macrophage infiltration and neutro-
phil degranulation are key features of pauci-immune
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Figure 2 | Serum levels of calprotectin in patients with renal and non-renal anti-neutrophil cytoplasm antibody (ANCA)-associated
vasculitis. (a) The level of serum calprotectin (ng/ml) in healthy controls (n¼ 16) and in patients with active ANCA–associated vasculitis (AAV)
(n¼ 57) and in patients with AAV in disease remission (n¼ 57). Patients with both active disease and in disease remission demonstrate
significantly higher levels of calprotectin than healthy controls (Po0.001, one-way analysis of variance (ANOVA)). There is also a significant
difference in levels between active disease and remission (Po0.001, one-way ANOVA). (b) Graph of 17 patients with serial calprotectin levels.
The patient highlighted in red illustrates a patient with a relapse. (c) Corresponding ANCA titers of the patients in graph (b). (d) Graph
demonstrating serum calprotectin levels in patients with early systemic non-renal involvement according to disease relapse after cessation of
treatment at 12 months. (e) Receiver operating curves (ROCs) using serum calprotectin levels to predict relapse in patients with limited
systemic disease using samples taken 1 month after treatment initiation. (f) ROC using serum calprotectin levels to predict relapse in patients
with limited systemic disease using samples taken 6 months after treatment initiation. AUC, area under the curve.
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glomerulonephritis secondary to AAV, whereas circulating
monocyte and neutrophil activation is found during active
disease. A previous study has demonstrated glomerular
macrophage expression of the heterodimer MRP8/14 (cal-
protectin, S100A8/A9) in patients with a variety of glomer-
ulonephritidies,16 including patients with active AAV who
demonstrated prominent expression in areas of necrotizing
extracapillary damage. However, this heterodimer is
reportedly absent from more chronic inflammatory
lesions.25 We found glomerular infiltration of calprotectin-
positive cells in the renal biopsies of patients with AAV.
Prominent calprotectin expression was seen within active
crescents and in areas of focal necrosis, but was absent in
sclerotic or normal glomeruli. Calprotectin expression
mirrored the histological lesions that predict better long-
term renal outcome according to the recent Berden
classification, with staining in the focal lesions and the
greatest staining in crescentic lesions, whereas long-term
outcome is best in focal glomerulonephritis followed by
crescentic glomerulonephritis.
In acute AAV, circulating monocytes and neutrophils are
activated. We found that patients with AAV have elevated
levels of cell surface calprotectin on both neutrophils and
monocytes compared with healthy controls, with levels
increasing further during active disease. In addition, serum
levels of calprotectin reflect these cellular findings, with
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Figure 3 | Flow cytometry to demonstrate the cell surface expression of calprotectin on monocytes and neutrophils in patients with
anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. (a) Flow cytometry plot demonstrating the identification of the
population of CD14-positive cells, neutrophils, and CD3-positive T lymphocytes. Monocytes were identified by anti-CD14 FITC antibody,
neutrophils by forward and side scatter, and T cells by anti-CD3 PE antibody. (b, c) Graph to demonstrate calprotectin surface expression of
(b) neutrophils and (c) CD14 cells in two individual patients (compared with isotype control). Shaded plot shows the FITC isotype control
antibody, whereas other plots show the increase in calprotectin-positive cells in a patient with active AAV (blue) and an ANCA–associated
vasculitis (AAV) remission patient (red). (d) Graph to demonstrate % gated neutrophils expressing extracellular calprotectin (% of positive cells
based upon gating of the isotype control) (controls vs. AAV active Po0.001, AAV active vs. AAV inactive Po0.05, one-way ANOVA). (e) Graph
showing % gated monocytes (CD14) expressing extracellular calprotectin, which follows a similar but nonsignificant trend to the neutrophils
(P¼NS) (d, e). Monocytes and neutrophils from active AAV (n¼ 10) patients demonstrate the highest surface expression of calprotectin
(controls n¼ 7, inactive AAV n¼ 18). (f) Mean fluorescent intensity (MFI) (calprotectin FITC antibody/isotype control antibody) of cells stained
for calprotectin, comparing controls, active AAV, and inactive AAV. There was a significant increase in the MFI on neutrophils from acute
patients compared with healthy controls (Po0.001). (g) MFI of calprotectin on monocytes demonstrating a significant increase in MFI between
patients with active disease and healthy controls (Po0.01).
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significantly higher levels in active disease compared with
remission and those found in healthy controls. Interestingly,
those patients in clinical remission still had persistently
elevated serum calprotectin levels and leukocyte expression,
suggesting that there is a degree of subclinical innate immune
activation. These data are reminiscent of other findings in
AAV remission, in which there is persistent monocyte
IL-12 and interferon gamma production,26 with augmented
indoleamine dioxygenase activation27 and elevated monocyte
TLR expression.28 Importantly, levels of calprotectin
diminished after therapy, but achieved lower degrees of
suppression in those patients who went on to relapse.
Analysis of receiver operating curve suggests that failure to
suppress calprotectin at 1 or 6 months may be a useful
predictor of future relapses, with a likelihood ratio of 10.3 at
1 month. This is significantly better than a rising ANCA titer,
which has recently been estimated in meta-analysis to
provide a likelihood ratio of 2.8 for disease relapse.4
However, as we did not have pretreatment levels, there
remains a possibility that relapsers simply maintain higher
levels of calprotectin. The levels at 1 month and 6 months
were measured when patients were receiving immuno-
suppression, which may partially account for the much
lower levels compared with those patients with renal
involvement. These results are similar to those found in
SLE.17,18 The most elevated levels in SLE have been seen with
arthritis and renal involvement, with a correlation between
the serum concentration and Systemic Lupus Erythematosus
Disease Activity Index, and no strong correlations between
cell surface levels and serum levels.29 In addition, a recent
study measuring S100A8/S100A9 (calprotectin) levels in
patients with early osteoarthritis demonstrated significantly
higher levels of S100A8/S100A9 in patients whose disease
progressed compared with the group of non-progressors.30
Patients with severe sepsis also demonstrate elevated levels of
calprotectin, although the levels are generally lower than
those seen in vasculitis patients, with no apparent correlation
between serum levels and severity on the infection.31
With regard to the source of serum calprotectin, we were
not able to demonstrate intracellular or surface expression of
the heterodimer in human umbilical vein endothelial cells at
rest or after stimulation with lipopolysaccharide (data not
shown), suggesting that most serum calprotectin is derived
from circulating neutrophils and monocytes.
We were not able to demonstrate a correlation between the
serum levels of calprotectin and the mRNA expression levels
in CD14 and CD16 cells, nor did we find significant changes
between patients and controls, suggesting that cellular
expression and secretion of calprotectin are not proportional
to the amount of the mRNA produced by the cell. However,
both serum levels and cell surface calprotectin expression are
augmented during disease activity, and in early systemic
disease higher levels are associated with disease relapse. These
findings suggest that serum calprotectin levels may help guide
immunosuppression treatment and may be of more clinical
utility than C-reactive protein, an acute-phase reactant,
which is generally within the normal range in patients during
remission and does not provide prognostic information.
A previous study in patients with juvenile idiopathic arthritis
treated with methotrexate demonstrated that higher levels of
MRP8/14 were predictive of flares, and reflected underlying
subclinical inflammation.23
Calprotectin (MRP8/14, S100A8/9), an example of a
damage-associated molecular pattern and a marker of activa-
tion of innate immunity, has recently been demonstrated to
have a role in autoimmunity and in induction of auto-
immune T cells, exerting its action through TLR4.32 TLR4
expression has been demonstrated in the kidney and has been
shown to contribute to renal injury in animal models.33
Furthermore, TLR4 expression on both bone marrow–
derived cells and glomerular endothelial cells has been shown
to have a role in neutrophil recruitment and renal injury in the
experimental myeloperoxidase glomerulonephritis model.34
In another animal model, S100A8 was able to upregulate
activatory FcgR in macrophages through binding TLR4.35
Recently, it has been demonstrated that neutrophil
extracellular traps (NETs) contain calprotectin36 and that
NETS are released by ANCA-stimulated neutrophils. The
formation of NETS may have a role in triggering vasculitis
and promoting the autoimmune response in patients with
small-vessel vasculitis.37
Overall, we demonstrate that calprotectin is upregulated
in patients with AAV and represents a marker of cellular
immune activation and disease activity. Larger prospective
trials of patients with generalized disease and long-term
follow-up should enable us to further define its prognostic
value in predicting disease relapse, with further investigations
required to demonstrate whether calprotectin could be
considered to have a role in vasculitis as a potential
biomarker.
MATERIALS AND METHODS
The samples were obtained from patients after informed consent
under local ethics committee approval (04/Q0406/25 Hammersmith
and Queen Charlotte’s & Chelsea Hospitals Research Ethics
Committee, 05/Q0508/6 Royal Free Hospital Research Ethics
Committee and 08/H0306/21 Cambidgeshire 3 Research Ethics
Committee).
IHC on renal biopsies
IHC was performed on formalin-fixed paraffin-embedded sections
using standard techniques staining for macrophages (anti-CD68)
and calprotectin using the Dako Envision system-HRP (Ely, UK)
(DAB (3,3-diaminobenzidine)). Antigen retrieval was performed
using a 0.1% calcium chloride solution in 0.5mM tris-buffered saline
with 1% trypsin (pH 7.8) for 10min at 37 1C. Primary antibodies
used were mouse anti-human CD68 (Dako)(dilution 1:25) or
mouse anti-human MRP8/14 (Bachem, Bubendorf, Switzerland)
(dilution 1:50). Isotype control antibody was used as a negative
control at the same dilution as the primary antibody. The primary
antibodies were incubated at room temperature in a humidified
chamber for 1 h. Peroxidase activity was detected with DAB. The
slides were then rinsed in water and counterstained with filtered
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Harris’ hematoxylin (Cell Path plc, Powys, UK); next, the slides were
dehydrated and mounted with DePeX Gurr mounting medium, and
coverslips were then placed. The slides were categorized according to
the recently described Berden classification for AAV,7 and the
quantification of calprotectin staining in both the glomerulus and
the interstitium was graded 0 (no staining) to 3 (extensive staining)
by blinded observers. Double staining was performed using anti-
CD15 (Dako), anti-CD68 (Dako), and polyclonal anti-MRP8/14
(Immundiagnostik AG, Bensheim, Germany). Antigen retrieval
was performed using the Leica epitope retrieval system for 30min
(anti-CD15) and 20min (anti-CD68) and Leica enzyme for
10min for anti-MRP8/14. The antibodies were incubated for 30min
at room temperature at the following dilutions: anti-CD15 and
anti-CD68, 1:50; and anti-MRP8/14, 1:2000. The sections were
developed using DAB for anti-CD15 and anti-CD68 and alkaline
phosphatase for anti-MRP 8/14 using the Leica Bond polymer refine
detection kits (Newcastle, UK). The Trio (Caliper Life Sciences,
Hopkinton, MA) multispectral imaging system was used to assess
the sections.
Subjects
AAV patients were identified through the vasculitis clinics at
hospitals in London (Royal Free and Hammersmith Hospitals) and
Cambridge (Addenbrooke’s Hospital).5 All fulfilled the Chapel
Hill Consensus criteria for diagnosis of either Granulomatosis
with polyangiitis (GPA, formerly Wegener’s granulomatosis) or
microscopic polyangiitis. Disease activity was assessed clinically,
biochemically, and histologically. Active disease at presentation
was defined by symptoms consistent with vasculitis, an elevated
Birmingham vasculitis activity score, and biochemical findings
demonstrating an acute inflammatory response, without evidence of
infection. Acute patients were either newly diagnosed, with positive
autoantibody serology, or in the case of ANCA-negative patients,
histological evidence of a pauci-immune glomerulonephritis, or
were known patients undergoing disease relapse which was defined
clinically as requiring an escalation in immunosuppression in order
to control disease activity. Acute blood samples were obtained where
possible before induction therapy initiation or shortly thereafter.
Remission patients were assessed by experienced clinicians and had
no symptoms related to active vasculitis, and had a Birmingham
vasculitis activity score of 0. Healthy controls were volunteers from
the individual units. In addition, serum samples stored from a
cohort of patients with limited systemic AAV, from the NORAM
trial38 conducted by the EUVAS, were also investigated.
Measurement of serum calprotectin levels
Serum was isolated from blood samples obtained from patients with
active disease, as well as from patients in disease remission and from
healthy controls. The serum from the patients in the NORAM trial
was obtained from the EUVAS serum bank and consisted of samples
from patients at 0–2 months from entry into the study and
commencement of immunosuppressive treatment with initial active
disease, at 5–7 months from entry when in remission on immunosup-
pressive treatment, and at 12–14 months from entry when a number of
patients had relapsed. In these patients, immunosuppression was
withdrawn at 12 months, with re-commencement of therapy in
those patients who had relapsed. Serum was stored at  20 1C until
analysis. Calprotectin levels were assessed by sandwich enzyme-
linked immunosorbent assay (BMA Biomedicals, Augst, Switzer-
land) according to the manufacturers’ instructions. Sample dilution
was optimized and incubated overnight at 4 1C before analysis the
following day.
Leukocyte cell surface calprotectin expression
Whole blood was collected from patients in EDTA and processed
shortly after collection. The sample was centrifuged at 2400 r.p.m.
for 5min to remove plasma. Red-cell lysis was carried out for 10min
at room temperature, followed by two washing steps. Extracellular
staining was performed with CD14 PE (BD Biosciences, Oxford,
UK), CD3 PE (eBioscience, Hatfield, UK), and calprotectin FITC
(Santa-Cruz Biotechnology, Santa Cruz, CA), as well as isotype
control antibodies. The cells were incubated with the antibodies on
ice for 30min, followed by two washing steps. Cells were fixed in 2%
paraformaldehyde before flow cytometry.
Separation of leukocyte subsets, extraction of RNA, and
microarray hybridization
The protocol is described in detail in Lyons et al.39 Briefly,
monocytes were obtained from density gradient–separated periph-
eral blood mononuclear cells by positive selection using CD14þ
microbeads. Neutrophils were obtained from the red-cell pellet by
positive selection using CD16þ microbeads after a red-cell lysis
step. RNA was then extracted using RNEasy mini kits (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
Double-stranded cDNA was then prepared, labeled with Cy5- or
Cy3-dCTP, and hybridized to custom-spotted ‘MEDIANTE’ oligo-
nucleotide microarrays prepared by the Centre for Microarray
Resources, Department of Pathology, University of Cambridge using
a two-color, dye-swap design. Spot intensities were extracted using
the Koadarray v2.4 software (Stirling, UK), background-corrected
and within-print-tip normalized. Preprocessing and subsequent
differential expression analysis for S100A8 and S100A9 was
performed using the limma package in R.39 The raw microarray
data are available on ArrayExpress under accession E-MTAB-157.
Statistics
Statistical analysis was performed using GraphPad Prism 4.0
(GraphPad software, San Diego, CA). Nonparametrc tests of
significance were carried out. A Mann–Whitney test was used when
comparing two groups. When comparing three or more groups, a
one-way ANOVA Kruskal–Wallis test with Dunn’s multiple compar-
isons was used. For correlation data, a Spearman rank correlation
test was applied. Receiver operating curve curves were calculated for
relapsing and non-relapsing patients in the NORAM study. Results
were significant when Po0.05.
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